HK186196A - Antagonist to interleukin-5 for preventing or reducing eosinophilia - Google Patents

Antagonist to interleukin-5 for preventing or reducing eosinophilia Download PDF

Info

Publication number
HK186196A
HK186196A HK186196A HK186196A HK186196A HK 186196 A HK186196 A HK 186196A HK 186196 A HK186196 A HK 186196A HK 186196 A HK186196 A HK 186196A HK 186196 A HK186196 A HK 186196A
Authority
HK
Hong Kong
Prior art keywords
cells
antagonist
vol
pgs
monoclonal antibody
Prior art date
Application number
HK186196A
Other languages
German (de)
English (en)
Inventor
L Coffman Robert
M Rennick Donna
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK186196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK186196A publication Critical patent/HK186196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)

Claims (6)

  1. Utilisation d'un antagoniste à l'interleukine-5 humaine dans la fabrication d'une composition pharmaceutique pour prévenir ou réduire l'éosinophilie chez un patient.
  2. Utilisation de la revendication 1, où ledit antagoniste à l'interleukine-5 humaine est choisi parmi un anticorps monoclonal capable de bloquer l'activité biologique de l'interleukine-5 humaine, un fragment d'un anticorps monoclonal capable de bloquer l'activité biologique de l'interleukine-5 humaine et une composition de liaison comprenant la région variable de chaîne lourde et la région variable de chaîne légère dans l'anticorps monoclonal capable de bloquer l'activité biologique de l'interleukine-5 humaine.
  3. Utilisation de la revendication 2, où ledit fragment dudit anticorps monoclonal est un fragment Fab.
  4. Utilisation de la revendication 2, où ledit anticorps monoclonal est produit par un hybridome humain-humain.
  5. Utilisation de la revendication 4, où ledit fragment dudit anticorps monoclonal est un fragment Fab.
  6. Utilisation de la revendication 2, où ladite composition pharmaceutique est adaptée à une fourniture intraveineuse d'une quantité dudit antagoniste,comprise entre environ 1-20 mg/kg de poids corporel dudit patient par jour.
HK186196A 1988-11-03 1996-10-03 Antagonist to interleukin-5 for preventing or reducing eosinophilia HK186196A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03

Publications (1)

Publication Number Publication Date
HK186196A true HK186196A (en) 1996-10-11

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
HK186196A HK186196A (en) 1988-11-03 1996-10-03 Antagonist to interleukin-5 for preventing or reducing eosinophilia

Country Status (17)

Country Link
EP (2) EP0367596B1 (fr)
JP (1) JPH07563B2 (fr)
KR (1) KR960002183B1 (fr)
AT (1) ATE98872T1 (fr)
AU (1) AU633034B2 (fr)
CA (1) CA2002144C (fr)
DE (1) DE68911653T2 (fr)
DK (1) DK81691A (fr)
ES (1) ES2062032T3 (fr)
HK (1) HK186196A (fr)
IE (1) IE63063B1 (fr)
IL (1) IL92180A (fr)
MY (1) MY107386A (fr)
NZ (1) NZ243939A (fr)
PH (1) PH26476A (fr)
WO (1) WO1990004979A2 (fr)
ZA (1) ZA898322B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2018226339A1 (fr) 2017-06-06 2018-12-13 Glaxosmithkline Llc Compositions biopharmaceutiques et procédés pour patients pédiatriques
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856566T2 (de) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen

Also Published As

Publication number Publication date
IL92180A (en) 1997-04-15
DE68911653T2 (de) 1994-04-07
IE63063B1 (en) 1995-03-22
WO1990004979A8 (fr) 2005-06-16
WO1990004979A2 (fr) 1990-05-17
DK81691D0 (da) 1991-05-02
PH26476A (en) 1992-07-27
ES2062032T3 (es) 1994-12-16
DK81691A (da) 1991-05-02
IL92180A0 (en) 1990-07-26
KR960002183B1 (ko) 1996-02-13
ZA898322B (en) 1990-11-28
NZ243939A (en) 1997-07-27
AU633034B2 (en) 1993-01-21
AU4644889A (en) 1990-05-28
EP0367596A1 (fr) 1990-05-09
JPH07563B2 (ja) 1995-01-11
IE893525L (en) 1990-05-03
EP0367596B1 (fr) 1993-12-22
JPH03505211A (ja) 1991-11-14
MY107386A (en) 1995-11-30
CA2002144C (fr) 2000-03-28
DE68911653D1 (de) 1994-02-10
CA2002144A1 (fr) 1990-05-03
ATE98872T1 (de) 1994-01-15
KR900701320A (ko) 1990-12-01
EP0441891A1 (fr) 1991-08-21

Similar Documents

Publication Publication Date Title
US5096704A (en) Method of treating eosinophilia
AU2005321017B2 (en) Monoclonal antibodies against NKG2A
CA1341477C (fr) Procede de reduction de la reaction a l'immunoglobuline e
EP0367596B1 (fr) Antagoniste de l'interleukin-5 pour prévenir ou réduire l'éosinophilie
EP0504307B1 (fr) Methode de traitement de choc septique
EP0347057A1 (fr) Traitement des leucemies myeloides
CA2079230C (fr) Antagonistes bcrf1 pour le traitement des infections dues au virus epstein-barr

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)